Is riluzole a new drug for Alzheimer's disease?

  • Daniel J. Whitcomb, Elek Molnár
  • Journal of Neurochemistry, September 2015, Wiley
  • DOI: 10.1111/jnc.13260

What is it about?

This Editorial highlights a study by Hunsberger et al. (2015) in the current issue of Journal of Neurochemistry, in which the authors explore the effects of riluzole (R) treatment on tau-P301L transgenic mice. The authors employed a comprehensive analysis of possible restorative effects of the drug by examining glutamate levels in subregions of the hippocampus, expression of tau and its hyper-phosphorylated forms, and memory function using behavioral tests. The authors report a simultaneous reduction in glutamate reuptake and an increase in glutamate release in the tau-P301L model, both of which are ameliorated with riluzole treatment. The authors' findings have implications for our understanding of synaptic transmission mechanisms also associated with Alzheimer's disease pathology.

Why is it important?

The authors' findings have implications for our understanding of synaptic transmission mechanisms also associated with Alzheimer's disease pathology.

Read Publication

http://dx.doi.org/10.1111/jnc.13260

The following have contributed to this page: Professor Elek Molnar